Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

Open access

Abstract

OBJECTIVE—To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI). RESEARCH DESIGN AND METHODS—In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six arms: 120, 240, and 360 μg b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI program geared toward weight loss. Of the 4-month evaluable subjects (n = 270), 77% opted to continue preexisting treatment during an 8-month single-blind extension (LSI geared toward weight maintenance). RESULTS—At month 4, mean weight loss from baseline in the pramlintide arms ranged from 3.8 ± 0.7 to 6.1 ± 0.8 kg (2.8 ± 0.8 kg with placebo). By month 12, initial 4-month weight loss was regained in the placebo group but was maintained in all but the 120-μg b.i.d. group. Placebo-corrected weight loss with 120 μg t.i.d. and 360 μg b.i.d. averaged 3.2 ± 1.2 kg (3.1 ± 1.1% body wt) and 3.3 ± 1.1 kg (3.1 ± 1.0% body wt), respectively, at month 4 (both P < 0.01; 4-month evaluable n = 270) and 6.1 ± 2.1 kg (5.6 ± 2.1% body wt) and 7.2 ± 2.3 kg (6.8 ± 2.3% body wt), respectively, at month 12 (both P < 0.01; 12-month evaluable n = 146). At month 12, 40 and 43% of subjects treated with 120 μg t.i.d. and 360 μg b.i.d., respectively, achieved ≥10% weight loss (vs. 12% for placebo). Nausea, the most common adverse event with pramlintide in the 4-month study (9–29% pramlintide vs. 2% placebo), was generally mild to moderate and occurred in <10% of subjects during the extension. CONCLUSIONS—When used over 12 months as an adjunct to LSI, pramlintide treatment, with low-dose three-times-daily or higher-dose two-times-daily regimens, helped obese subjects achieve greater initial weight loss and enhanced long-term maintenance of weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc08-0029

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Changes in body weight (kg) from baseline (month 0) for twice-daily (A) and three-times-daily (B) dosing regimens. For the double-blind study, data are presented from months 0–4 for the 4-month evaluable population (n = 270). For the single-blind extension, data are presented from months 4–12 for the 12-month evaluable population (n = 146) and at 12 months for the 12-month ITT population (LOCF) (n = 209). There are two data points for the 4-month assessment: one assessment for subjects ending the double-blind study and another for subjects entering the single-blind extension. For clarity, only month 4 and month 12 significance for double-blind study and single-blind extension, respectively, are depicted. ○ = placebo; ▴ = 120 μg pramlintide; ▵ = 240 μg pramlintide; • = 360 μg pramlintide. Data are mean ± SE. *P < 0.05 and **P < 0.01 for each pramlintide treatment group versus placebo.
Figure 1 Changes in body weight (kg) from baseline (month 0) for twice-daily (A) and three-times-daily (B) dosing regimens. For the double-blind study, data are presented from months 0–4 for the 4-month evaluable population (n = 270). For the single-blind extension, data are presented from months 4–12 for the 12-month evaluable population (n = 146) and at 12 months for the 12-month ITT population (LOCF) (n = 209). There are two data points for the 4-month assessment: one assessment for subjects ending the double-blind study and another for subjects entering the single-blind extension. For clarity, only month 4 and month 12 significance for double-blind study and single-blind extension, respectively, are depicted. ○ = placebo; ▴ = 120 μg pramlintide; ▵ = 240 μg pramlintide; • = 360 μg pramlintide. Data are mean ± SE. *P < 0.05 and **P < 0.01 for each pramlintide treatment group versus placebo.CC BY-NC-ND · PubMed Central
Figure 2 Proportion of 12-month evaluable subjects who achieved ≥5% (A) and ≥10% (B) weight loss from baseline (month 0) to month 12. Changes in body weight from baseline (month 0) to month 12 for each 12-month evaluable individual in the placebo (C), pramlintide 120 μg t.i.d. (D), and pramlintide 360 μg b.i.d. (E) treatment arms. *P < 0.05 for each pramlintide treatment group versus placebo.
Figure 2 Proportion of 12-month evaluable subjects who achieved ≥5% (A) and ≥10% (B) weight loss from baseline (month 0) to month 12. Changes in body weight from baseline (month 0) to month 12 for each 12-month evaluable individual in the placebo (C), pramlintide 120 μg t.i.d. (D), and pramlintide 360 μg b.i.d. (E) treatment arms. *P < 0.05 for each pramlintide treatment group versus placebo.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 1

  1. National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report [article online], 1998 (NIH publ. no. 98-4083). Available from http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/obesity/obesity.pdf. Accessed 8 December 2005

Cited by

Metadata

Authors
Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C.
Affiliations
  • Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana
  • Weill Cornell Medicine (US)
  • Amylin Pharmaceuticals, San Diego, California
Venue
Diabetes Care
Published
2008-09-01
Volume
31
Issue
9
Pages
1816-1823
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2170571946
Cited by
172
References
19
Citations by year
2026: 11 · 2025: 17 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 15 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 3 · 2013: 11 · 2012: 16
FWCI
10.78
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • European Foundation for the Study of Diabetes
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
pramlintide, obesity, weight loss, lifestyle intervention, GLP-1 receptor agonists, dose-ranging, weight maintenance, nausea, adverse events, long-term efficacy, weight regain
MeSH terms
Adult, Amyloid, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Life Style, Male, Middle Aged, Placebos, Time Factors, Weight Loss, Body Mass Index, Single-Blind Method, Body Size, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.